Journal
PROGRESS IN RETINAL AND EYE RESEARCH
Volume 82, Issue -, Pages -Publisher
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.preteyeres.2020.100906
Keywords
Neovascular age-related macular degeneration; Choroidal neovascularization; Anti-VEGF; Anti-VEGF resistance; Persistent disease activity; Suboptimal vision recovery; Macrophage; Monocyte; Mesenchymal precursor cell; Neovascular remodeling; Photoreceptor synaptic dysfunction; Miller cell
Categories
Funding
- National Institutes of Health (NIH) [R01 EY018880]
- NIH [R01 EY013318, R03 EY015292, K08 EY025325, K08 EY026627, P30 EY005722]
- Research to Prevent Blindness Grant
- Stealth BioTherapeutics
- Bausch + Lomb
Ask authors/readers for more resources
This review explores the pathobiology, clinical manifestations, and treatment approaches for incomplete response to anti-VEGF therapy in NVAMD patients, focusing on persistent disease activity (PDA) and suboptimal vision recovery (SVR). Findings suggest that patients with high-flow CNV lesions are more prone to PDA, while poor vision recovery may be associated with dysfunction in photoreceptor synaptic function in the neurosensory retina.
Intravitreal anti-vascular endothelial growth factor (VEGF) drugs have revolutionized the treatment of neovascular age-related macular degeneration (NVAMD). However, many patients suffer from incomplete response to anti-VEGF therapy (IRT), which is defined as (1) persistent (plasma) fluid exudation; (2) unresolved or new hemorrhage; (3) progressive lesion fibrosis; and/or (4) suboptimal vision recovery. The first three of these collectively comprise the problem of persistent disease activity (PDA) in spite of anti-VEGF therapy. Meanwhile, the problem of suboptimal vision recovery (SVR) is defined as a failure to achieve excellent functional visual acuity of 20/40 or better in spite of sufficient anti-VEGF treatment. Thus, incomplete response to anti-VEGF therapy, and specifically PDA and SVR, represent significant clinical unmet needs. In this review, we will explore PDA and SVR in NVAMD, characterizing the clinical manifestations and exploring the pathobiology of each. We will demonstrate that PDA occurs most frequently in NVAMD patients who develop high-flow CNV lesions with arteriolarization, in contrast to patients with capillary CNV who are highly responsive to anti-VEGF therapy. We will review investigations of experimental CNV and demonstrate that both types of CNV can be modeled in mice. We will present and consider a provocative hypothesis: formation of arteriolar CNV occurs via a distinct pathobiology, termed neovascular remodeling (NVR), wherein blood-derived macrophages infiltrate the incipient CNV lesion, recruit bone marrow-derived mesenchymal precursor cells (MPCs) from the circulation, and activate MPCs to become vascular smooth muscle cells (VSMCs) and myofibroblasts, driving the development of high-flow CNV with arteriolarization and perivascular fibrosis. In considering SVR, we will discuss the concept that limited or poor vision in spite of anti-VEGF may not be caused simply by photoreceptor degeneration but instead may be associated with photoreceptor synaptic dysfunction in the neurosensory retina overlying CNV, triggered by infiltrating blood-derived macrophages and mediated by Miller cell activation Finally, for each of PDA and SVR, we will discuss current approaches to disease management and treatment and consider novel avenues for potential future therapies.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available